Lovastatin ® (bevacizumab) is approved by CFDA for combination chemotherapy of non-small cell lung cancer

On July 7, Roche announced that its antineoplastic drug avidin ® (general name: Bevacizumab) has been approved by the State Food and Drug Administration of China and will be used as the first-line treatment for advanced metastatic non-small cell non-scale lung cancer The approved marketing of avidin ® not only provides a new treatment option for Chinese lung cancer patients, but also opens up a new pattern of anti angiogenic treatment for lung cancer in China As the world's first anti-tumor angiogenesis drug, avidin ® has been approved for treatment of multiple solid tumors in more than 120 countries and regions, benefiting millions of patients At the same time, Roche will support the China Charity Association to launch the avidin non-small cell lung cancer patient assistance project simultaneously, so as to help low-income lung cancer patients get timely and effective assistance The detailed rules for the implementation of the project will be published on the official website of China Charity Association in the near future Relevant information shall be subject to the detailed rules published by China Charity Association Bevacizumab can effectively prolong the survival period of lung cancer patients Bevacizumab is an antibody that can specifically bind and block vascular endothelial growth factor (VEGF) It plays a role by inhibiting angiogenesis This mechanism can effectively help control tumor growth and metastasis without increasing the side effects of chemotherapy According to the results of the first phase III clinical study of bevacizumab for lung cancer patients in China, the beyond study shows that the combination of bevacizumab and chemotherapy can bring significant survival benefits, reduce the risk of death and improve the quality of life of patients with advanced lung cancer The data showed that compared with traditional chemotherapy, bevacizumab combined chemotherapy prolonged the progression free survival time by 2.7 months (9.2 months vs 6.5 months, P = 0.0001), and the total survival time by 7.2 months (24.3 months vs 17.1 months, P = 0.0154) The results showed that patients who received bevacizumab combined therapy had a 60% lower risk of disease progression and a 32% lower risk of death than those who received chemotherapy alone Continuous innovation and R & D to benefit more lung cancer patients is Roche's key research and development area, as well as the main investment area For a long time, Roche has been committed to the development of innovative drugs and bringing them to patients suffering from lung cancer, a fatal disease Currently, Roche has two globally approved drugs for specific lung cancer In addition, the R & D product line of Roche lung cancer has 10 kinds of lung cancer drugs including immunotherapy and targeted therapy for specific driving genes With the development of individualized medical technology, these drugs may benefit more lung cancer patients in the future (BIOON Com)